Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Baxter’s Fourth-Quarter Profit Beats Analysts’ Estimates

Baxter International's Office Stands in Toronto
Baxter International Inc. signage is displayed outside of the company's office in Toronto. Baxter said sales gained 16 percent in the fourth quarter of 2013, boosted by demand for hemophilia treatments and medical products, as well as its acquisition of Gambro AB. Photographer: Brent Lewin/Bloomberg

Baxter International Inc., a maker of dialysis products, reported fourth-quarter profit that beat analysts’ estimates on demand for hemophilia therapies.

Fourth-quarter earnings, excluding one-time items, of $1.26 a share beat by 1 cent the average of 15 analyst estimates compiled by Bloomberg.

Sales rose 16 percent to $4.4 billion, boosted by the Advate and Feiba hemophilia treatments and the acquisition of Sweden’s Gambro AB, Deerfield, Illinois-based Baxter said in a statement today. Earnings excluding one-time items for 2014 will probably be $5.05 to $5.25 a share, the company said. The outlook excludes 25 cents in amortization expenses.

“Overall, performance in the quarter looked solid,” Derrick Sung, an analyst with Sanford C. Bernstein & Co., wrote in a research note today. Baxter’s forecast missed his estimate of $5.29 a share, he said. “The weaker outlook raises some questions.”

Baxter declined 1.1 percent to $69 at the close of trading in New York. The shares have gained 3.6 percent in the last 12 months.

Net income in the quarter fell 34 percent to $326 million, or 59 cents a share, from $494 million, or 89 cents, a year earlier, Baxter said. The results were weighed down by $366 million in one-time items that included the cost of acquiring Gambro, the company said.

Baxter said in December 2012 it agreed to acquire Gambro for 18.3 billion kronor ($2.8 billion), adding a unit with about $1.6 billion in annual sales.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.